Literature DB >> 2319405

Pigmentary abnormalities and mosaicism for chromosomal aberration: association with clinical features similar to hypomelanosis of Ito.

V P Sybert1, R A Pagon, M Donlan, C M Bradley.   

Abstract

Thirteen patients with hypopigmentation of the skin characteristic of hypomelanosis of Ito, and with developmental disabilities or structural malformations, or both, were examined at our center. Eight were found to have abnormal karyotypes in lymphocytes, fibroblasts, or both. No single clinical feature was predictive of chromosome imbalance in this group of patients. Cytogenetic findings included a balanced de novo X-autosome translocation; ring 10; 45,X/46,X,+ring; mosaic del 13q11 (fibroblasts); mosaic triploidy (fibroblasts); mosaic tetrasomy 12p (fibroblasts); mosaic apparently balanced 15;22 translocation (peripheral blood); and mosaic trisomy 18 (peripheral blood). Hypomelanosis of Ito is characterized by swirly hypopigmentation or depigmentation of the skin with or without other malformations. Autosomal dominant, autosomal recessive, and X-linked dominant inheritance have been suggested but not confirmed. Chromosomal aneuploidy has also been reported. We believe that hypomelanosis of Ito is an etiologically heterogeneous physical finding, and recommend karyotyping of multiple tissues of all patients with abnormal cutaneous pigmentation associated with developmental delay or structural malformations.

Entities:  

Mesh:

Year:  1990        PMID: 2319405     DOI: 10.1016/s0022-3476(05)81606-3

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  17 in total

1.  "Cutis tricolor": congenital hyper- and hypopigmented macules associated with a sporadic multisystem birth defect: an unusual example of twin spotting?

Authors:  R Happle; G Barbi; D Eckert; I Kennerknecht
Journal:  J Med Genet       Date:  1997-08       Impact factor: 6.318

Review 2.  Hypomelanosis of Ito and X;autosome translocations: a unifying hypothesis.

Authors:  E Hatchwell
Journal:  J Med Genet       Date:  1996-03       Impact factor: 6.318

3.  Functional Xp disomy and de novo t(X;13)(q10;q10) in a girl with hypomelanosis of Ito.

Authors:  L S Correa-Cerro; H Rivera; A I Vasquez
Journal:  J Med Genet       Date:  1997-02       Impact factor: 6.318

4.  X inactivation analysis in a female with hypomelanosis of Ito associated with a balanced X;17 translocation: evidence for functional disomy of Xp.

Authors:  E Hatchwell; D Robinson; J A Crolla; A E Cockwell
Journal:  J Med Genet       Date:  1996-03       Impact factor: 6.318

5.  Hypomelanosis of Ito in a girl with plexus papilloma and translocation (X;17).

Authors:  E Steichen-Gersdorf; R Trawöger; H C Duba; U Mayr; S Felber; G Utermann
Journal:  Hum Genet       Date:  1993-02       Impact factor: 4.132

6.  Mosaicism with a normal cell line and an autosomal structural rearrangement.

Authors:  R J Gardner; H E Dockery; P H Fitzgerald; R G Parfitt; D R Romain; N Scobie; R L Shaw; P Tumewu; A J Watt
Journal:  J Med Genet       Date:  1994-02       Impact factor: 6.318

7.  Asymmetry and skin pigmentary anomalies in chromosome mosaicism.

Authors:  C G Woods; A Bankier; J Curry; L J Sheffield; S F Slaney; K Smith; L Voullaire; D Wellesley
Journal:  J Med Genet       Date:  1994-09       Impact factor: 6.318

Review 8.  Heterogeneous seizure manifestations in Hypomelanosis of Ito: report of four new cases and review of the literature.

Authors:  Komi Assogba; Edoardo Ferlazzo; Pasquale Striano; Tiziana Calarese; Nathalie Villeneuve; Ivan Ivanov; Placido Bramanti; Edoardo Sessa; Iliana Pacheva; Pierre Genton
Journal:  Neurol Sci       Date:  2009-11-10       Impact factor: 3.307

9.  Pigmentary mosaicism: an update.

Authors:  Rajoo Thapa
Journal:  Indian J Dermatol       Date:  2008       Impact factor: 1.494

10.  Mosaic loss of 15q11q13 in a patient with hypomelanosis of Ito: is there a role for the P gene?

Authors:  J E Pellegrino; R E Schnur; R Kline; E H Zackai; N B Spinner
Journal:  Hum Genet       Date:  1995-10       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.